Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 16;11(29):7091-7100.
doi: 10.12998/wjcc.v11.i29.7091.

Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma

Pei Wang  1 , Sheng-Yu Jin  2
Affiliations

Meta-analysis of the efficacy and safety of daratumumab in the treatment of multiple myeloma

Pei Wang et al. World J Clin Cases. .

Abstract

Background: The treatment of multiple myeloma has significantly progressed over the past half-century. The purpose of this study was to perform a systematic review and meta-analysis in order to explore the efficacy and safety of daratumumab in treating multiple myeloma.

Aim: To explore the efficacy and safety of daratumumab in treating multiple myeloma.

Methods: A systematic literature search was performed using Chinese and English databases, including the China National Knowledge Infrastructure, Wanfang, China Biology Medicine, VIP, the Cochrane Library, Embase, and PubMed. The search encompassed studies in treating multiple myeloma with daratumumab, spanning from the inception of the database to June 2023. Revman 5.1 software was used for analysis.

Results: Our analysis included eight English articles and one Chinese article of high quality. The meta-analysis results indicated that compared to other therapies, daratumumab could improve the overall response rate (ORR) [odds ratio (OR) = 2.67, 95% confidence interval (CI) = 2.01, 3.53, Z = 6.85, P < 0.00001], complete remission (CR) (OR = 2.87, 95%CI = 2.16, 3.83, Z = 7.23, P < 0.00001) and progression-free survival (PFS) time (hazard ratio = 0.48, 95%CI = 0.38,0.60, Z = 6.54, P < 0.00001) in patients with multiple myeloma. These differences were statistically significant. Additionally, these results suggested that daratumumab increases the risk of neutropenia and thrombocytopenia with minimal effect on the incidences of anemia and upper respiratory tract infections.

Conclusion: Daratumumab can improve ORR, CR rate, and PFS in patients with multiple myeloma. It also increases the risk of neutropenia and thrombocytopenia, necessitating careful monitoring during its clinical application.

Keywords: Daratumumab; Efficacy; Meta-analysis; Multiple myeloma; Safety.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All author reports have no conflicts of interest.

Figures

Figure 1
Figure 1
Screening flow chart.
Figure 2
Figure 2
Quality evaluation plot.
Figure 3
Figure 3
Forest plot of the combined results of daratumumab and other therapies in patients with multiple myeloma. A: Progression-free survival time; B: Overall response rate; C: Complete remission; D: Incidence of neutropenia; E: Incidence of anemia; F: Incidence of thrombocytopenia; G: Upper respiratory tract infection; H: Sensitivity analysis. MM: Multiple myeloma; PFS: Progression-free survival time; ORR: Overall response rate; CR: Complete remission; CI: Confidence interval.
Figure 4
Figure 4
Funnel plot of the incidence of adverse event. A: Thrombocytopenia; B: Neutropenia.
See this image and copyright information in PMC

References

    1. Afifi S, Michael A, Lesokhin A. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab. Ann Pharmacother. 2016;50:555–568. - PMC - PubMed
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. - PMC - PubMed
    1. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. - PMC - PubMed
    1. Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34:1875–1884. - PMC - PubMed
    1. Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Yang H, Klippel Z, Zahlten-Kumeli A, Usmani SZ. Carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186–197. - PubMed